SHEBA MEDICAL CENTER

Minovia Therapeutics received a $350,000 grant from Countdown for a Cure Foundation to develop novel mitochondrial blood-based biomarkers for patient identification and treatment monitoring.

Multiply Labs' robotic biomanufacturing cluster achieves a 74% cost reduction in cell therapy production through collaborative robot arms from Universal Robots, as demonstrated in peer-reviewed studies with UCSF.

Researchers at Sheba Medical Center and Tel Aviv University have successfully grown human fetal kidney components from tissue stem cells for up to 34 weeks, marking the first time such organoids have survived beyond four weeks in laboratory conditions.

Researchers from Tel Aviv University and Sheba Medical Center have developed a bioengineered skin graft using patients' own cells that heals burns in half the time of standard treatments.

Mentaily, founded in 2024, raised $3 million in seed funding to advance its AI-powered mental health assessment platform LIV, which simulates clinical psychiatric intake sessions with high diagnostic accuracy.

Tethis S.p.A. and Sheba Medical Center have launched a research collaboration to evaluate circulating tumor cells in rectal cancer patients using Tethis' proprietary See.d® technology.

Inspira Technologies has integrated a next-generation oxygenation indicator into its HYLA blood sensor, enabling continuous monitoring of tissue oxygenation without blood draws.

Ursodeoxycholic acid (UDCA), while groundbreaking, leaves up to 40% of Primary Biliary Cholangitis patients with inadequate response, highlighting the need for additional treatment options.

Israel's healthtech sector is thriving, ranking third globally in tech company density and driving innovation in AI-driven healthcare and precision medicine.

Early research suggests CBD may help curb SARS-CoV-2 replication in infected cells, warranting further investigation through rigorous clinical trials.